Vital Biopharmaceutical Insights and Analytics

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Featured Report
Gastric Cancer (Unresectable): An Emerging Biological Agent Will Take Over as Market Leader in 2013

For the treatment of gastric cancer, Roche/Genentech/ Chugai’s Herceptin as an add-on to standard chemotherapy earns Decision Resources’ proprietary clinical gold standard status in 2013 ...Learn More

Featured Webinar
Will the Lack of Efficacious Therapies Open the Door for a New Clinical Gold Standard in Obesity Treatment?

March 17, 2010...Learn More

View Webinar schedule and archive

Search Reports

Filter results:

TOP TEN REPORTS

See which reports have been searched on the most.

In the Spotlight

	Matthew J. Winton, Ph.D. March 18, 2010 10 a.m. ET, 4 p.m. CET
In this presentation, Dr. Winton will discuss the impact of Dimebon’s clinical trial failure on the Alzheimer’s disease drug market… Learn more

Latest Press Releases [ view all ]

March 11, 2010

Stimuvax Will Become Decision Resources’ Proprietary Clinical Gold Standard for the Treatment of Locally Advanced Non-Small-Cell Lung Cancer ...Read More
March 10, 2010

An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists ...Read More
March 10, 2010

Limited Healthcare Infrastructure and Weak Intellectual Property Protection Are Among the Challenges Pharma Faces With Emerging Market Expansion ...Read More

Recent Reports [ view all ]

Complicated Skin and Skin Structure Infections: Recent FDA Nonapprovals Leave Untapped Opportunity for Emerging Broad-Spectrum MRSA Agents

Complicated skin and skin structure infections (cSSSIs) is an important market for antibiotic drug developers because... Read More
Colorectal Cancer (Stage IV): Blockbuster Opportunity Awaits a Therapy That Would Improve Overall Survival over IFL/Bevacizumab

The pipeline for stage IV colorectal cancer (CRC) comprises a wide range of therapies, from drugs designed to enhance... Read More
Strategic Overview of Pricing and Reimbursement in the BRIC Markets

A country whose pharma market is predicted to grow at 21.8% annually merits the attention of the pharma industry. That... Read More